


**INTRAVENOUS INFUSIONS PLC**  
MANUFACTURERS OF PHARMACEUTICAL PRODUCTS  
*"Saving lives since 1969"*

---

**Intravenous Infusions PLC**  
**Unaudited Financial Statements for the**  
**Six Months Ended 30 June 2024**



**INTRAVENOUS INFUSIONS PLC**  
MANUFACTURERS OF PHARMACEUTICAL PRODUCTS  
*"Saving lives since 1969"*

**KEY FINANCIAL HIGHLIGHTS**

	30 JUNE 2024 UNAUDITED GH¢	30 JUNE 2023 UNAUDITED GH¢	% CHANGE YOY
Revenue	12,614,849	13,570,159	-7%
Gross Profit	6,920,755	8,051,640	-14%
Finance Costs	361,318	126,343	186%
Operating Profit	980,658	2,706,911	-64%
Net Profit/(Loss) before tax	619,340	2,580,568	-76%
Net Shareholders' funds	17,825,327	16,875,435	6%
Cash and cash Equivalent	539,533	1,715,203	-69%


**UNAUDITED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME**

	30 JUNE 2024 UNAUDITED GH¢	30 JUNE 2023 UNAUDITED GH¢	% CHANGE YOY
Revenue	12,614,849	13,570,159	-7%
Cost of operations	(5,694,094)	(5,518,519)	3%
<b>Gross profit</b>	<b>6,920,755</b>	<b>8,051,640</b>	<b>-14%</b>
Other income	3,094	324	855%
Operating and other expenses	(5,943,191)	(5,345,053)	11%
<b>Profit before finance cost and tax</b>	<b>980,658</b>	<b>2,706,911</b>	<b>-64%</b>
Finance cost	(361,318)	(126,343)	186%
<b>Profit before tax</b>	<b>619,340</b>	<b>2,580,568</b>	<b>-76%</b>
Income tax expense	(116,126)	(483,857)	-76%
<b>Profit for the period</b>	<b>503,214</b>	<b>2,096,711</b>	<b>-76%</b>
Earnings per share	0.0018	0.0076	-76%

**UNAUDITED STATEMENT OF FINANCIAL POSITION**

	30 JUNE 2024 UNAUDITED GH¢	30 JUNE 2023 UNAUDITED GH¢	% CHANGE YOY
<b>ASSETS</b>			
<b>Non-current assets</b>			
Property, plant and equipment	23,335,267	22,230,562	5%
Investment	9,720		100%
<b>Current assets</b>			
Inventory	6,980,362	7,669,720	-9%
Trade and other receivables	16,823,785	20,319,882	-17%
Cash	539,533	1,715,203	-69%
<b>Total current assets</b>	<b>24,343,680</b>	<b>29,704,805</b>	<b>-18%</b>
<b>Total assets</b>	<b>47,688,667</b>	<b>51,935,367</b>	<b>-8%</b>
<b>Equity</b>			
Stated capital	11,626,451	11,626,451	0%
Retained earnings	4,095,756	3,145,864	30%
Capital surplus	2,103,120	2,103,120	0%
<b>Total equity</b>	<b>17,825,327</b>	<b>16,875,435</b>	<b>6%</b>
<b>Non-Current Liability</b>			
Deferred Tax liability	393,673	262,317	56%
Lease Obligation	34,279		100%
Medium term loan	9,973,735	13,807,378	-28%
<b>Total Non- current liability</b>	<b>10,401,687</b>	<b>14,059,695</b>	<b>-26%</b>
<b>Current liabilities</b>			
Borrowings	1,089,341	2,140,376	-49%
Trade and other payables	18,372,312	18,859,861	-3%
Current tax	0	0	0%
Employee Benefit obligation	0	0	0%
<b>Total Current Liabilities</b>	<b>19,461,653</b>	<b>21,000,237</b>	<b>-7%</b>
<b>Total Liabilities</b>	<b>29,863,340</b>	<b>35,059,932</b>	<b>-15%</b>
<b>Total Liabilities and Equity</b>	<b>47,688,667</b>	<b>51,935,367</b>	<b>-8%</b>





### UNAUDITED STATEMENT OF CHANGES IN EQUITY

	Stated capital	Deposit for shares	Income surplus	Capital surplus	Total
Balance at 1 <sup>st</sup> Jan 2024	11,626,451		3,592,542	2,103,120	17,322,113
issue of shares(net)					
Profit/(Loss) for the period					
Dividend paid					
Transfer from profit and loss			503,314		503,314
At 30 <sup>th</sup> June 2024	<b>11,626,451</b>		<b>4,095,756</b>	<b>2,103,120</b>	<b>17,825,327</b>

### UNAUDITED STATEMENT OF CASH FLOWS

	30 JUNE 2024 UNAUDITED GH¢	30 JUNE 2023 UNAUDITED GH¢
<b>Operating activities</b>		
Profit before tax	619,340	2,580,568
<b>Adjustments for non-cash income and expenses:</b>		
Net employee obligation		
Depreciation of property, plant and equipment	397,255	275,926
<b>Cash flow included in operating activities</b>	<b>1,016,595</b>	<b>2,856,494</b>
<b>Changes in operating assets and liabilities</b>		
Decrease/increase in trade and other receivables	(223,467)	(3,698,055)
Increase/decrease in trade payables	2,178,680	3,184,172
Increase/decrease in inventory	(720,474)	(1,042,870)
<b>Cash flow from operating activities</b>	<b>2,251,334</b>	<b>1,299,741</b>
Tax paid		
Dividend paid		
<b>Net cash from operating activities</b>	<b>2,251,334</b>	<b>1,299,741</b>
<b>Cash flows from investing activities</b>		
Purchases of equipment	(5,689)	(15,050)
<b>Net cash used in investing activities</b>	<b>(5,689)</b>	<b>(15,050)</b>



**INTRAVENOUS INFUSIONS PLC**  
MANUFACTURERS OF PHARMACEUTICAL PRODUCTS  
*"Saving lives since 1969"*

<b>Cash flows from financing activities</b>		
Increase in borrowings	(1,999,745)	(521,977)
<b>Net cash used in financing activities</b>	<b>(1,999,745)</b>	<b>(521,977)</b>
<b>Net (increase/decrease) in cash and cash equivalents</b>	<b>(245,900)</b>	<b>762,714</b>
Cash and cash equivalents at beginning of year	293,633	952,489
<b>Cash and cash equivalents at 30 June 2024</b>	<b>539,533</b>	<b>1,715,203</b>

**Moukhtar Soalih**  
**(Managing Director)**

**Eugenia Bulley**  
**(General Manager, Finance and Administration)**